Semaglutide

Semaglutide is a long-acting GLP-1 receptor agonist primarily utilized for weight management, obesity, and glycemic control. While clinical protocols typically involve daily oral doses ranging from 500 µg to 2 mg, community users report a wider spectrum of administration, with 1 mg being the most common daily dose. Users occasionally report experiencing nausea, gastrointestinal distress, edema, or changes in sleep patterns. Readers should note that while the substance is well-established for its primary indications, the evidence base for its numerous exploratory uses remains thin, with many potential applications currently lacking published results.

Half-life~7 days

Data last updated

ClinicalResearchDepthClinicalResearchEfficacyClinicalResearchSideEffectsAnecdotalEfficacyAnecdotalSideEffectsPrice3.74.81.13.92.44.0

Research Evidence

Evidence shape

Semaglutide carries a high evidence tier, supported by extensive clinical literature confirming its efficacy for Type 2 diabetes and obesity. With 475 registered trials and 48 blinded studies featuring results, the data depth is substantial, spanning diverse metabolic and cardiovascular indications. While the peptide is well-validated for its primary uses, the vast majority of its 157 mapped indications remain exploratory or limited to single-trial investigations. This breadth indicates a wide range of ongoing research, though many potential applications currently lack the robust, multi-trial confirmation seen in its core clinical indications.

Depthhow much
473 registered trials
233 completed · 73 with posted results · 200 recruiting / active · combined n=807802
Breadthhow many areas
158 indications mapped
12 with results · 143 thin / exploratory · 1 animal-only · 116 single-trial long-tail
Qualityhow rigorous
Highest tier: Phase 3
48 blinded with results · 59 distinct sponsors · AE rows aggregated from 68 trials · 31 linked publications on registered trials
Breadth and depth503 rows captured
Human
direct clinical signal
488
Animal
translational support
12
In vitro
mechanistic support
3
HighMediumLow

Anecdotal efficacy

Semaglutide side effects

Clinical research side effects

Anecdotal side effects

Price

Full buying guide →
1
BOC Peptide
--
300 mg×10
$110.00
$0.37/mg
2
Mrbeetoe
--
50 mg
$40.00
$0.8/mg
3
BulkGLP
USA
1000 mg
$1,699.00
$1.7/mg
4
Peppyandme
US
20 mg
$40.00
$2/mg
5
Lilipeptide
China
10 mg
$21.00
$2.1/mg
6
Metbio Peptides
--
30 mg
$64.99
$2.17/mg

price offers can be sorted by column

1-6 of 169

Semaglutide dosing & protocol

How Semaglutide is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols · n = 244
Typical dose
2.4 mg500 µg – 50 mg
typical
0
10 mg
20 mg
30 mg
40 mg
50 mg
distribution of 111 reported doses · darker = more
Frequency
weekly
Route
subQ

In the trials summarized, semaglutide was administered subcutaneously at a typical dose of 2.4 mg once weekly, with individual study doses ranging from 0.5 mg to 3 mg weekly.

244 sources
Clinician practice
Doctor & published-protocol guidance · n = 3
Typical dose
500 µg500 µg – 2 mg
typical
0
10 mg
20 mg
30 mg
40 mg
50 mg
distribution of 7 reported doses · darker = more
By reported cadence· tap a row to filter the chart
Frequency
daily
Route
oral

For clinician practice, semaglutide is administered orally at 500 mcg once daily; sources report a daily range of 0.5 mg to 1 mg.

3 sources
Anecdotal
Community-reported real-world use · n = 61
Typical dose
1 mg125 µg – 14 mg
typical
0
10 mg
20 mg
30 mg
40 mg
50 mg
distribution of 65 reported doses · darker = more
By stated route· tap a row to filter the chart
Frequency
unspecified
Route
subQ

Users typically take 500 mcg subcutaneously, with reported doses ranging from 250 mcg to 14 mg; most do not specify frequency, while a smaller group reports weekly dosing.

61 sources

Regulatory safety notes

Warnings and precautions
  • • Acute Pancreatitis : Has been observed in patients treated with GLP-1 receptor agonists, including RYBELSUS or OZEMPIC tablets. Discontinue if pancreatitis is suspected. •
  • • Diabetic Retinopathy Complications : Has been reported in a cardiovascular outcomes trial with semaglutide injection. Patients with a history of diabetic retinopathy should be monitored. •
  • • Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin : May increase the risk of hypoglycemia, including severe hypoglycemia. Reducing the dosage of insulin secretagogue or insulin may be necessary. •
  • • Acute Kidney Injury Due to Volume Depletion : Monitor renal function in patients reporting adverse reactions that could lead to volume depletion. •
  • • Severe Gastrointestinal Adverse Reactions : Use of RYBELSUS or OZEMPIC tablets has been associated with gastrointestinal adverse reactions, sometimes severe. RYBELSUS and OZEMPIC tablets are not recommended in patients with severe gastroparesis. •
  • • Hypersensitivity Reactions : Serious hypersensitivity reactions (e.g., anaphylaxis and angioedema) have been reported. Discontinue RYBELSUS or OZEMPIC tablets if hypersensitivity reactions occur and monitor until signs and symptoms resolve. •
  • • Acute Gallbladder Disease : If cholelithiasis or cholecystitis are suspected, gallbladder studies are indicated. •
  • • Pulmonary Aspiration During General Anesthesia or Deep Sedation : Has been reported in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures. Instruct patients to inform healthcare providers of any planned surgeries or procedu…
Contraindications
  • • RYBELSUS and OZEMPIC tablets are contraindicated in
  • • patients with: • A personal or family history of medullary thyroid carcinoma (MTC) or in
  • • patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Warnings and Precautions (5.1) ] . • A prior serious hypersensitivity reaction to semaglutide or to any of the excipients in RYBELSUS or OZEMPIC ta…
  • • patients with MEN 2 syndrome type 2 • Prior serious hypersensitivity reaction to semaglutide or any of the excipients in OZEMPIC
Drug interactions
  • • Drugs : RYBELSUS and OZEMPIC tablets delay gastric emptying. Consider increased clinical or laboratory monitoring when co-administered with other oral medications that have a narrow therapeutic index or that require clinical monitoring. (7.2)

Related peptides

TirzepatideRetatrutideSurvodutideAOD-9604CagrilintideOrforglipronLiraglutideExenatideTesamorelinEloralintideTesofensineMazdutide